“We’ve hit the wall in terms of how much more we can leverage an antibody,” says David Apelian, MD, PhD. As the CEO of BlueSphere Bio, Apelian is more than willing to consider alternatives to antibodies. Indeed, BlueSphere is interested in developing therapies that rely on T-cell receptors (TCRs). The company is already using TCR technology to seize opportunities presented by blood-based and solid tumors.